Abcellera Biologics Inc
ABCL4.170USD
-0.050-1.18%
Handelsschluss 09/08, 16:00（ET）Kurse um 15 Minuten verzögert
1.25BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Abcellera Biologics Inc Unternehmen
AbCellera Biologics Inc. discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. The Company’s engine integrates technology, data science, infrastructure, and interdisciplinary teams to solve the antibody discovery problems. The Company has developed technology platforms to unlock drug classes, targets, and modalities, including transmembrane proteins, T-cell engagers, and peptide-MHCs. The Company is focused on advancing an internal pipeline of programs and collaborating on drug development programs with partners. Its first two preclinical programs in its internal pipeline are ABCL575 and ABCL635. ABCL635 is an antibody-drug candidate against an undisclosed target with an indication in metabolic and endocrine conditions. ABCL575 targets OX40 ligand and is being developed as a therapy for the treatment of atopic dermatitis and other indications of autoimmunity and inflammation.
Unternehmensinformationen
BörsenkürzelABCL
Name des UnternehmensAbcellera Biologics Inc
IPO-datumDec 11, 2020
CEODr. Carl L.G. Hansen, Ph.D.
Anzahl der mitarbeiter596
WertpapierartOrdinary Share
GeschäftsjahresendeDec 11
Addresse150 W 4Th Avenue
StadtVANCOUVER
BörseNASDAQ Global Select Consolidated
LandCanada
PostleitzahlV5Y 1G6
Telefon16045599005
Websitehttps://www.abcellera.com/
BörsenkürzelABCL
IPO-datumDec 11, 2020
CEODr. Carl L.G. Hansen, Ph.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Veronique Lecault, Ph.D.
Dr. Veronique Lecault, Ph.D.
Co-Founder, Chief Operating Officer, Director
Co-Founder, Chief Operating Officer, Director
9.61M
--
Mr. Andrew Booth
Mr. Andrew Booth
Chief Financial Officer
Chief Financial Officer
283.96K
--
Mr. Tryn T. Stimart, J.D.
Mr. Tryn T. Stimart, J.D.
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer
--
--
Dr. Andrew W. Lo, Ph.D.
Dr. Andrew W. Lo, Ph.D.
Independent Director
Independent Director
--
--
Mr. John S. Montalbano
Mr. John S. Montalbano
Independent Director
Independent Director
--
--
Dr. Carl L.G. Hansen, Ph.D.
Dr. Carl L.G. Hansen, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Chairman of the Board, President, Chief Executive Officer, Co-Founder
--
--
Dr. Michael R. Hayden
Dr. Michael R. Hayden
Lead Independent Director
Lead Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Veronique Lecault, Ph.D.
Dr. Veronique Lecault, Ph.D.
Co-Founder, Chief Operating Officer, Director
Co-Founder, Chief Operating Officer, Director
9.61M
--
Mr. Andrew Booth
Mr. Andrew Booth
Chief Financial Officer
Chief Financial Officer
283.96K
--
Mr. Tryn T. Stimart, J.D.
Mr. Tryn T. Stimart, J.D.
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer
--
--
Dr. Andrew W. Lo, Ph.D.
Dr. Andrew W. Lo, Ph.D.
Independent Director
Independent Director
--
--
Mr. John S. Montalbano
Mr. John S. Montalbano
Independent Director
Independent Director
--
--
Dr. Carl L.G. Hansen, Ph.D.
Dr. Carl L.G. Hansen, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Chairman of the Board, President, Chief Executive Officer, Co-Founder
--
--
Umsatzaufteilung
Währung: USDAktualisiert: Sat, Feb 22
Währung: USDAktualisiert: Sat, Feb 22
FY2024Q2
FY2023Q2
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Research fees
5.45M
74.46%
Milestone payments
1.50M
20.48%
Licensing revenue
370.00K
5.05%
Keine Daten
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Research fees
5.45M
74.46%
Milestone payments
1.50M
20.48%
Licensing revenue
370.00K
5.05%
Aktionärsstatistik
Aktualisiert: Sat, Aug 16
Aktualisiert: Sat, Aug 16
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Thermopylae Holdings Ltd
18.79%
Baker Bros. Advisors LP
9.21%
Capital World Investors
4.47%
Baillie Gifford & Co.
3.47%
Lecault (Veronique)
3.22%
Andere
60.85%
Aktionäre
Aktionäre
Anteil
Thermopylae Holdings Ltd
18.79%
Baker Bros. Advisors LP
9.21%
Capital World Investors
4.47%
Baillie Gifford & Co.
3.47%
Lecault (Veronique)
3.22%
Andere
60.85%
Aktionärstypen
Aktionäre
Anteil
Corporation
18.79%
Hedge Fund
16.22%
Investment Advisor
15.65%
Individual Investor
4.15%
Investment Advisor/Hedge Fund
2.99%
Bank and Trust
1.20%
Private Equity
1.13%
Research Firm
0.63%
Venture Capital
0.32%
Andere
38.92%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
372
214.57M
71.89%
-123.81K
2025Q1
429
202.31M
67.85%
-22.54M
2024Q4
453
194.86M
65.41%
-21.40M
2024Q3
451
190.45M
64.55%
-29.37M
2024Q2
449
195.17M
66.27%
-23.48M
2024Q1
442
202.34M
69.21%
-22.49M
2023Q4
434
206.18M
71.07%
-38.61M
2023Q3
437
216.53M
74.89%
-39.50M
2023Q2
439
222.03M
76.83%
-29.38M
2023Q1
423
223.82M
78.22%
-38.92M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Thermopylae Holdings Ltd
56.14M
18.81%
--
--
Apr 01, 2025
Baker Bros. Advisors LP
27.53M
9.22%
--
--
Mar 31, 2025
Capital World Investors
13.36M
4.48%
+5.43M
+68.41%
Mar 31, 2025
Baillie Gifford & Co.
11.20M
3.75%
-1.04M
-8.50%
Mar 31, 2025
Lecault (Veronique)
9.61M
3.22%
--
--
Apr 01, 2025
Two Sigma Investments, LP
5.77M
1.93%
-94.12K
-1.60%
Mar 31, 2025
UBS Asset Management (Americas) LLC
6.61M
2.21%
+6.61M
--
Mar 31, 2025
ArrowMark Colorado Holdings, LLC
4.11M
1.38%
--
--
Mar 31, 2025
UBS Asset Management (Switzerland)
9.06M
3.04%
+4.56M
+101.35%
Mar 31, 2025
UBS Switzerland AG
5.05M
1.69%
+4.91M
+3556.81%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Wed, Aug 6
Aktualisiert: Wed, Aug 6
Name
Anteil
iShares Genomics Immunology and Healthcare ETF
1.77%
TrueShares Technology, AI & Deep Learning ETF
1.53%
Virtus LifeSci Biotech Clinical Trials ETF
0.98%
Invesco Nasdaq Biotechnology ETF
0.13%
ProShares Ultra Nasdaq Biotechnology
0.11%
iShares Biotechnology ETF
0.1%
SPDR S&P International Small Cap ETF
0.07%
Invesco RAFI Developed Mkts ex-US SM ETF
0.02%
Avantis US Small Cap Equity ETF
0.01%
SPDR Portfolio Developed World ex-US ETF
0.01%
Mehr Anzeigen
iShares Genomics Immunology and Healthcare ETF
Anteil1.77%
TrueShares Technology, AI & Deep Learning ETF
Anteil1.53%
Virtus LifeSci Biotech Clinical Trials ETF
Anteil0.98%
Invesco Nasdaq Biotechnology ETF
Anteil0.13%
ProShares Ultra Nasdaq Biotechnology
Anteil0.11%
iShares Biotechnology ETF
Anteil0.1%
SPDR S&P International Small Cap ETF
Anteil0.07%
Invesco RAFI Developed Mkts ex-US SM ETF
Anteil0.02%
Avantis US Small Cap Equity ETF
Anteil0.01%
SPDR Portfolio Developed World ex-US ETF
Anteil0.01%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
